Target Name: MAPRE3
NCBI ID: G22924
Review Report on MAPRE3 Target / Biomarker Content of Review Report on MAPRE3 Target / Biomarker
MAPRE3
Other Name(s): Microtubule-associated protein RP/EB family member 3 | EB1 protein family member 3 | RP3 | MARE3_HUMAN | EBF3-S | MAPRE3 variant 1 | microtubule associated protein RP/EB family member 3 | End-binding protein 3 | EBF3 | EB3 | Microtubule associated protein RP/EB family member 3, transcript variant 1 | APC binding protein | end-binding protein 3

MAPRE3: A Potential Drug Target and Biomarker for Microtubule-associated Protein RP/EB Family Member 3

Microtubules (MTs) are a type of protein structure that is found in the cytoskeleton of eukaryotic cells. They play a crucial role in cell division, intracellular transport, and other cellular processes. The MTs are composed of a protein called tubulin and a protein called microtubule-associated protein (MAP) which helps to regulate the assembly and disassembly of the MTs.MAPRE3 is a member of the MAP family, which includes proteins that are involved in the regulation of microtubules. It is a protein that is found in the cytosol of eukaryotic cells and it has been shown to play a role in the regulation of microtubule dynamics.

MAPRE3 has been shown to interact with several other proteins, including the protein kinase B-complex. This interaction between MAPRE3 and B-complex suggests that MAPRE3 may be a drug target for the treatment of various diseases.

One of the potential therapeutic applications of MAPRE3 is its potential as a treatment for neurodegenerative diseases, such as Alzheimer's disease. Neurodegenerative diseases are characterized by the progressive loss of brain cells and the damage to the nervous system. There is a significant need for new treatments for these diseases, and MAPRE3 may be a valuable target for the development of new therapies.

MAPRE3 has also been shown to be involved in the regulation of cancer cell division. It has been shown to inhibit the division of cancer cells, which may be a potential therapeutic approach for the treatment of cancer.

MAPRE3 may also be a useful biomarker for certain diseases. For example, it has been shown to be involved in the regulation of the growth and differentiation of various cell types, which may be relevant to the development of certain diseases.

In conclusion, MAPRE3 is a protein that has been shown to play a role in the regulation of microtubule dynamics and has potential as a drug target and biomarker for various diseases. Further research is needed to fully understand its role and potential as a therapeutic approach.

Protein Name: Microtubule Associated Protein RP/EB Family Member 3

Functions: Plus-end tracking protein (+TIP) that binds to the plus-end of microtubules and regulates the dynamics of the microtubule cytoskeleton (PubMed:28814570, PubMed:19255245). Promotes microtubule growth (PubMed:28814570, PubMed:19255245). May be involved in spindle function by stabilizing microtubules and anchoring them at centrosomes (PubMed:28814570, PubMed:19255245). Also acts as a regulator of minus-end microtubule organization: interacts with the complex formed by AKAP9 and PDE4DIP, leading to recruit CAMSAP2 to the Golgi apparatus, thereby tethering non-centrosomal minus-end microtubules to the Golgi, an important step for polarized cell movement (PubMed:28814570). Promotes elongation of CAMSAP2-decorated microtubule stretches on the minus-end of microtubules (PubMed:28814570)

The "MAPRE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAPRE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MAPT | MAPT-AS1 | MAPT-IT1 | MARCHF1 | MARCHF10 | MARCHF11 | MARCHF11-DT | MARCHF2 | MARCHF3 | MARCHF4 | MARCHF5 | MARCHF6 | MARCHF6-DT | MARCHF7 | MARCHF8 | MARCHF9 | MARCKS | MARCKSL1 | MARCO | MARF1 | MARK1 | MARK2 | MARK2P5 | MARK2P9 | MARK3 | MARK4 | MARS1 | MARS2 | MARVELD1 | MARVELD2 | MARVELD3 | MAS1 | MAS1L | MASP1 | MASP2 | MAST1 | MAST2 | MAST3 | MAST4 | MASTL | MAT1A | MAT2A | MAT2B | MATCAP1 | MATCAP2 | MATK | MATN1 | MATN1-AS1 | MATN2 | MATN3 | MATN4 | MATR3 | Matrix Metalloproteinase (MMP) | MAU2 | MAVS | MAX | MAZ | MB | MB21D2 | MBD1 | MBD2 | MBD2-MBD3 complex | MBD3 | MBD3L1 | MBD3L2 | MBD3L3 | MBD3L4 | MBD3L5 | MBD4 | MBD5 | MBD6 | MBIP | MBL1P | MBL2 | MBLAC1 | MBLAC2 | MBNL1 | MBNL1-AS1 | MBNL2 | MBNL3 | MBOAT1 | MBOAT2 | MBOAT4 | MBOAT7 | MBP | MBTD1 | MBTPS1 | MBTPS2 | MC1R | MC2R | MC3R | MC4R | MC5R | MCAM | MCAT | MCC | MCCC1 | MCCC2 | MCCD1 | MCCD1P1